A ‘nightmare bacteria’ is surging while investment in antibiotics lags

A ‘nightmare bacteria’ is surging while investment in antibiotics lags is a pharma and life sciences industry update from PharmaVoice. The story may affect commercial strategy, market access planning, stakeholder engagement, competitive positioning, and near-term monitoring for pharmaceutical and biotech teams.

Kelly Bilodeau · 2026-06-25

Experts are sounding the alarm about the rise in drug-resistant superbugs and urging more action.

Source: PharmaVoice